AI x Bio's wild 48 hours: OpenAI buys Orchestra Bio, 15+ launches
vaibhavbetter · x · 2026-10-23
A roundup of the past 48 hours in AI x biotech, likened to "ferociously laying optical fiber in 1999":
- Deals & deployment: OpenAI acquires Orchestra Bio; Biomni+Bayer and Boltz+BMS model deployments; Warp Sciences' AI-driven robotic drug-discovery labs
- Model releases: Carbon-X open DNA interpretation model; Holon-S1 cancer biomarkers from pathology slides; Pinal protein design from plain language; Vitrify molecular simulations beyond DFT accuracy; Bindwell's Atomwell binding-affinity model; Baker Lab's RFD4-Proteina; BioEmu2
- Clinical milestones: Omnii-1, an AI-designed phage given to a patient; Claude-designed scorpion toxin binders
- Infra: Chaperone, an agent framework for protein design
The density suggests AI x Bio is in its infrastructure-building phase.
More from Venture
- Hong Kong Kid Pitches an AI Video Ads Business to a Street Interviewer On Camera — aakashgupta · 2026-10-23
- AI clones spark debate: how much moat is left for feature-only software? — sven_ai · 2026-10-23
- Why short-timeliners should expect tens-of-billions AI lab acquisitions, not technical evals — herbiebradley · 2026-10-23
- SF Home Sells $10M Over Asking as Blogger Mocks Risk-Averse Indian VCs — vaibhavbetter · 2026-10-23
- Vercel founder Suhail publicly offering to buy RL kernel optimisation tasks for models — AIFlow_ML · 2026-10-23
- OpenAI lowers valuation target to raise up to $30 billion in new round — The Decoder · 2026-10-23